MultiVir withdraws IPO; RapidMist buccal delivery tech finds partner;

> Cancer gene therapy company MultiVir withdrew its $60 million IPO. More

> Generex is collaborating with NHTherapeutics. The companies will utilize Generex's RapidMist buccal delivery technology to deliver Leuprolide for the treatment of hypogonadism and other endocrine disorders. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.